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Effect of Tocotrienols enriched canola oil on 
glycemic control and oxidative status in patients 
with type 2 diabetes mellitus: A randomized 
double-blind placebo-controlled clinical trial
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1Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran, 2Endocrine Research Center, Firouzgar 
Hospital, Iran University of Medical Sciences, 3Department of Nutrition, School of Paramedicine, Ahvaz Jundishapur University of Medical 
Sciences, Ahvaz, Iran, 4Nutrition and Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of 
Medical Sciences, Tehran, Iran, 5Department of Endocrinology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
the pathogenesis and complications of type 2 diabetes.[4-6] It 
has been proposed that antioxidants may improve insulin 
action and reduce the complications in DM.[7-9]
Vitamin E consists of two classes of biologically active 
substances named tocopherols and tocotrienols, and 
four vitamers in each class (α, β, γ and δ). Although 
all tocopherols and tocotrienols have a share structure 
which possesses antioxidant activity, each member has 
unique biological actions.[10] Tocotrienols are thought to 
INTRODUCTION
Diabetes mellitus (DM), a complex and progressive 
disease, is associated with higher risk of cardiovascular 
disease and premature death.[1,2] The antioxidant system is 
challenged in patients with diabetes by increased oxidative 
stress due to hyperglycemia, hyperinsulinemia, and 
insulin resistance.[3] Oxidative stress has been implicated in 
Background: Tocotrienols have been shown to improve glycemic control and redox balance in an animal study, but their effects on 
patients with diabetes are unknown. The study aimed to investigate whether tocotrienols improves glycemic control, insulin sensitivity, 
and oxidative stress in individuals with type 2 diabetes mellitus (T2DM). Materials and Methods: This study was a double-blinded, 
placebo-controlled, randomized trial. A total of 50 patients, aged 35-60 years, with T2DM treated by noninsulin hypoglycemic drugs 
were randomly assigned to receive either 15 mL/day tocotrienols (200 mg) enriched canola oil (n = 25) or pure canola oil (n = 25) 
for 8 weeks. Fasting blood sugar (FBS), fasting insulin, total antioxidant capacity (TAC), malondialdehyde (MDA), and homeostatic 
model assessment for insulin resistance (HOMA-IR) were determined before and after the intervention. The data were compared 
between and within groups, before and after the intervention. Results: Baseline characteristics of participants including age, sex, 
physical activity, disease duration, and type of drug consumption were not significantly different between the two groups. In tocotrienol 
enriched canola oil, FBS (mean percent change: –15.4% vs. 3.9%; P = 0.006) and MDA (median percent change: –35.6% vs. 16.3%; 
P = 0.003) were significantly reduced while TAC was significantly increased (median percent change: 21.4% vs. 2.3%; P = 0.001) 
compared to pure canola oil. At the end of the study, patients who treated with tocotrienols had lower FBS (P = 0.023) and MDA 
(P = 0.044) compared to the pure canola oil group. However, tocotrienols had no effect on insulin concentrations and HOMA-IR. 
Conclusion: Tocotrienols can improve FBS concentrations and modifies redox balance in T2DM patients with poor glycemic control 
and can be considered in combination with hypoglycemic drugs to better control of T2DM.
Key words: Diabetes mellitus, hyperglycemia, oxidative stress, randomized controlled trial, tocotrienols
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be more efficient than the α-tocopherol in scavenging free 
radicals as a result of a better distribution in the fatty layer 
of cell membrane.[11,12] Some beneficial effects of tocotrienols 
that are often not exhibited by tocopherols, including 
hypocholesterolemic,[13] anti-cancer,[14] neuroprotective,[15,16] 
and anti-inflammatory properties[17] have been reported 
recently. However, tocotrienols have been less studied 
than tocopherols, and the most data were derived from in 
vitro or animal studies.[10] There are very limited data from 
human intervention studies, so the functional implications 
of tocotrienols properties are not yet fully determined.
In human studies, tocotrienol-rich fraction (TRF) derived 
from rice bran oil or palm oil were associated with reduced 
oxidative stress in healthy participants,[18,19] and improved 
lipid profile in hypercholesterolemic individuals[13] and 
patients with diabetes.[20] The synergistic effect of tocotrienols 
and lovastatin on lipid profile in hypercholesterolemic 
humans was also demonstrated.[21]
Although their purported properties suggest that 
tocotrienols could be useful to improve diabetes control and 
to prevent the development of its chronic complications, 
the possible benefits of tocotrienols administration as 
an adjuvant therapy for the treatment of DM, based on 
a randomized controlled trial, are limited and deserve 
further investigation.[20,22] We have therefore examined 
the effects of tocotrienols rich Vitamin E preparation from 
palm oil on fasting blood sugar (FBS), fasting insulin 
concentrations, the homeostatic model assessment for 
insulin resistance (HOMA-IR), total antioxidant capacity 
(TAC) and malondialdehyde (MDA) in individuals with 
type 2 DM (T2DM).
MATERIALS AND METHODS
Study design and participants
In this randomized, double-blind placebo-controlled 
trial, 50 patients with type 2 diabetes participated. The 
participants were recruited from the Endocrinology and 
Metabolism Center of Iran University of Medical Sciences 
between November 2011 and April 2012. Applicants could 
be included in the study if they were aged 35-60 years, 
had a body mass index (BMI) of <40 kg/m2, and diabetes 
had been diagnosed at least 1-year before the study based 
on the American Diabetes Association (FBS ≥126 mg/dL 
or 2 h-plasma glucose (2h-PG) ≥200 mg/dL or treated 
with hypoglycemic medications).[4] Pregnant or lactating 
women, those suffering from renal, liver, thyroid, cancer, 
inflammatory or infectious disease, treating with insulin, 
anti-inflammatory or anti-coagulant drugs, smoking, 
and taking alcohol were excluded from the study. No 
participants had taken any vitamin or mineral supplements 
for at least 1-month prior to the study. The objectives and 
protocol of the study were explained to the participants, 
who expressed their written informed consent to participate. 
Five patients, two in tocotrienols enriched canola oil group 
(one person due to immigration and the other due to 
changing in treatment protocol) and three in pure canola 
group (first one due to inability to walk to center, second 
due to unavailable enough blood serum and the third due to 
unwilling to end the study), withdrew the study [Figure 1]. 
No adverse events were reported during the study. To 
monitor adherence to intervention, a close supervision of 
all participants was carried out through personal contact 
weekly. Compliance, assessed by measuring the remaining 
volume of oil in the returned bottles, was more than 95%.
The study was approved by the Ethics Committee of the 
School of Public Health of Tehran University of Medical 
Sciences and was registered at the Iranian Registry of 
Clinical Trials (IRCT) as IRCT201008092365N2.
Randomization
Participants were divided into two groups randomly. 
Randomization was carried out by means of a random 
number table; for this, an independent coordinator created 
the randomization list assigning participants to the 
tocotrienols enriched canola oil or pure canola oil group. 
Two bottles of oil were provided to each participant for 
consuming during each 4-week period. Each bottle was 
returned at the end of 4-week duration. These identical 
bottles of tocotrienols enriched canola oil and pure canola 
oil were provided unlabeled and then an independent 
coordinator labeled these bottles with subject numbers 
(1-50) using the randomization list. Both the participants 
and the research team members were blinded to the 
treatment allocation.
Preparation of tocotrienol enriched canola oil
A palm-based mixture of Vitamin E tocotienol was prepared 
commercially (Vitrenol, P.T. MUSIM MAS Manufacturer, 
Indonesia) and it contained approximately 51% tocols 
(total tocotrienols and tocopherols). The mixture consisted 
of approximately 38.4% total tocotrienols (including 
13.2% α-tocotrienols and 16.6% γ-tocotrienols) and 16% 
α-tocopherol. In the lab, 29,400 mg Vitrenol added to 810 g 
canola oil. Thus, a tablespoon of canola oil (15 mL) contained 
approximately 525 mg Vitrenol, 200 mg total tocotrienols, 
69.3 mg α-tocotrienols and 87.15 mg γ-tocotrienols. Adding 
tocotrienols to canola oil did not change its appearance, taste 
or smell. Tocotrienols enriched canola oil and pure canola 
oil was placed into identical bottles.
Interventions
The intervention group received 15 mL/day of tocotrienols 
enriched canola oil (n = 25), containing 200 mg/day total 
tocotrienols, and control group received the same amount 
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of pure canola oil for 8 weeks. Participants ingested 15 mL/
day of the oil after lunch or dinner, as preferred, by adding 
a tablespoon of the oil to their cooked foods or salad. Since 
Vitamin E isomers are sensitive to heat and oxidation, 
they were requested to avoid using the oil in the cooking 
process. They were also asked to maintain their usual diet 
and physical activity throughout the study.
Biochemical evaluations and other measurements
Blood samples were collected before and after the intervention 
after 10-12 h overnight fast and before taking the hypoglycemic 
drugs. Blood Serum was obtained by centrifugation at 
3000-4000 rpm for 10 min. Serum FBS was measured by the 
glucose-oxidase method (Pars Azmun kit, Iran) and insulin 
concentrations were measured by radioimmunoassay 
(Immunotech kit, France). HOMA-IR was calculated as fasting 
glucose (mg/dL) × fasting insulin (µIU/mL)/405.
TA C  wa s  d e t e r m i n e d  u s i n g  2 , 2 - a z i n o - b i s - 3 -
ethylbenzothiazoline-6-sulfonic acid (ABTS) method[23] 
with minor modification. Bovin serum albumin (BSA), 
the Trolox equivalent antioxidant activity was used as a 
standard.[24,25] The assay is based on the generation of a 
stable blue-green color radical cation (ABTS•+) from a 
reaction of metmyoglobin and H2O2 producing a radical 
that interacts with the chromogen ABTS. When the colored 
ABTS•+ is combined with antioxidants, it is reduced to the 
colorless form of ABTS. Quenching of absorbance of this 
species at 734 nm by antioxidants was quantified and then 
compared to the one from BSA as a standard.[25] Serum MDA 
concentrations were determined by colorimetric method.[26]
Dietary intakes were monitored by 3-day 24 h food recall, 
including 2 weeks day and 1 weekend day, at entry and 
end of the study, and the daily nutrient intakes (energy, 
carbohydrate, protein, fat, Vitamin C and E, zinc and selenium) 
were determined using Nutritionist 4 software (N-squared 
Computing, San Bruno, CA, USA). Physical activity levels were 
assessed by the International Physical Activity Questionnaire 
at beginning and end of the study and expressed as low (<600 
Met-min/week) and moderate (>600 Met-min/week) physical 
activity.[27] Body weight and height were measured before and 
after intervention and BMI was calculated as body weight (kg) 
divided by height squared (m2).
Statistical analyses
The number of participants estimated for each group was 
21 at 80% power and α of 0.05 to detect a difference of 
Figure 1: Study participants flow chart
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11 mg/dL in FBS concentrations between groups with an 
standard deviation (SD) of 12.8.[20] To allow for dropouts, 
it was decided to recruit 25 participants for each group. 
Analyses were based on the participants who completed 
the study.
The Kolmogorov-Smirnov test was applied to assess 
normality of data. Data for continuous variables with 
normal distribution are presented as mean ± SD while 
nonnormally distributed data are presented as medians 
and percentiles 25 and 75 (25th, 75th percentile). Normally 
distributed data within groups were compared using 
paired samples t-test and between groups by independent-
samples t-test. Comparison of nonnormally distributed 
data was conducted using Wilcoxon signed ranks and the 
Mann-Whitney U-test. The percent change for variables was 
also calculated as (week 8 values − baseline values)/baseline 
values × 100. Categorical variables are presented as n (%) 
and compared between two groups by Chi-square test. We 
used the SPSS software (version 15.0; SPSS Inc., Chicago, 
IL, USA) for all the statistical analyses. A two-tailed P ≤ 0.05 
was considered significant statistically.
RESULTS
Baseline characteristics of the 45 participants who 
completed the study are shown in Table 1. There were no 
significant differences between the groups in regard of age, 
sex, weight, height, BMI, physical activity, disease duration, 
and type of drug consumption (P > 0.05). Likewise, no 
significant changes were observed for weight, BMI, and 
physical activity levels throughout the study (P > 0.05). 
The hypoglycemic agents used were metformin (n = 10) 
and glibenclamide alone (n = 16) or in combination (n = 19) 
from the beginning of the study, in doses that remained 
unchanged during the study (P = 0.303).
Dietary intake of energy, carbohydrate, protein, fat, Vitamin 
C and E, zinc and selenium, as determined by the 3-day food 
recall without considering 15 mL added canola oil, were not 
significantly different between the two groups before and 
after the intervention [Table 2].
Effects of tocotrienols on glycemic control and oxidative 
stress are presented in Table 3. FBS, insulin and HOMA-IR 
were not different between the two groups at the study entry, 
while TAC was lower )3.37 ± 0.83 vs. 4.26 ± 0.54; P < 0.001) 
and MDA was higher (3.22 ± 1.41 vs. 2.31 ± 1.19; P < 0.001) 
in the tocotrienols enriched canola oil group, significantly. 
Tocotrienols enriched canola oil consumption resulted in 
significant reductions in FBS (P = 0.003) and MDA (P < 0.001) 
concentrations compared to baseline values. After 8-week, 
the FBS and MDA concentrations were significantly lower 
in tocoterienol enriched canola oil compared with pure 
canola oil group (P = 0.023 and P = 0.044, respectively). TAC 
concentration was increased in tocotrienols enriched canola 
oil compared with baseline values (4.22 ± 0.48 vs. 3.37 ± 
0.83; P < 0.001,) but its concentration was not significantly 
Table 1: Baseline characteristics of patients with T2DM 
treated by tocotrienol enriched canola oil or pure canola oil
Variables Tocotrienol 
enriched canola 
oil (n = 23)
Pure 
canola oil 
(n = 22)
Pa
Age, years 55.9±5.9b 55.2±5.6 0.709
Female, n (%) 18 (78.3) 15 (68.2) 0.445
Weight (kg) 64.5±17.1 68.5±12.0 0.374
Height (cm) 160.8±8.0 161.7±10.1 0.756
BMI (kg/m2) 25.1±6.9 26.1±3.3 0.533
Low physical activity level, 
n (%)
13 (56.0) 12 (54.5) 0.899
Moderate physical activity 
level, n (%)
10 (44) 10 (45.5)
Duration of disease, years 4.8±4.1 4.7±2.9 0.923
Hypoglycemic medications, 
n (%)
Metformin 7 (30.4) 3 (13.6) 0.303
Glibenclamide 6 (26.1) 10 (45.5)
Metformin+glibenclamide 10 (43.5) 9 (40.9)
aP values refer to comparisons between groups (independent t-test or Chi-square 
test as appropriate); bMean ± SD (all such values). BMI = Body mass index; 
T2DM = Type 2 diabetes mellitus; SD = Standard deviation
Table 2: Changes of dietary intakes of participants before and after the interventiona
Variable Tocotrienol enriched canola 
oil (n = 23)
Pb Pure canola oil (n = 22) Pb Pc Pd
Week 0 Week 8 Week 0 Week 8
Energy (kcal/day) 3191±1136 3540±1456 0.32 2928±1051 2867±1734 0.74 0.07 0.12
Carbohydrate (g/day) 416±159 507±149 0.25 400±173 410±216 0.44 0.36 0.43
Protein (g/day) 88±32 103±54 0.08 88±32 95±32 0.17 0.78 0.32
Total fat (g/day) 139±59 119±42 0.17 115±56 111±38 0.55 0.32 0.56
Vitamin C (mg/day) 199±85 192±142 0.22 157±56 174±96 0.71 0.21 0.54
Vitamin E (mg/day) 17±17 20±41 0.49 19±9 19±38 0.86 0.66 0.93
Zinc (mg/day) 10±4 11±4 0.66 10±3 9±3 0.64 0.41 0.32
Selenium (mg/day) 0.1±0.03 0.1±0.04 0.51 0.1±0.05 0.1±0.05 0.32 0.71 0.41
aMean ± SD; bP values refer to comparisons between week 0 and week 8 within groups (paired t-test or Wilcoxon as appropriate); cP values refer to comparisons between groups 
after intervention (independent t-test or Mann-Whitney U-test as appropriate); dP value refer to comparisons changes of mean difference between groups (independent t-test or 
Mann-Whitney U-test as appropriate). SD = Standard deviation
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different between two groups at the end of the study (4.22 ± 
0.48 vs. 4.44 ± 0.43; P = 0.132). No significant effect was 
observed regarding insulin concentration and HOMA-IR.
Percent changes of variables in the two groups are shown 
in Figure 2. Mean/medians for percent changes during 
the study were significant in FBS (mean percent change: 
−15.4% vs. 3.9%; P = 0.006), MDA (median percent change: 
−35.6% vs. 16.3%; P = 0.003), and TAC (median percent 
change: 21.4% vs. 2.3%; P = 0.001) when tocotrienols 
enriched canola oil was compared with pure canola oil.
DISCUSSION
Diabetes is associated with substantial premature 
death from various diseases including cancer, vascular 
diseases, infectious diseases, and degenerative disease. 
Continuous associations between fasting glucose 
concentrations >100 mg/dL and risk of death suggest that 
hyperglycemia may be directly relevant to premature 
death in diabetes. These findings also reinforce the 
need to control and maintain FBS near to normal 
concentrations in DM.[2]
Table 3: Changes of FBS, insulin, HOMA-IR, TAC, MDA before and after 8 weeks of follow-up between tocotrienol 
enriched canola oil versus pure canola oil
Variables Tocotrienol enriched canola oil (n = 23) Pc Pure canola oil (n = 22) Pc Pd
FBS (mg/dL)
Week 0 136.0 (121.0, 173.0)a 0.003 152.0 (115.0, 179.2) 0.754 0.733
Week 8 121.0 (98.0, 140.0) 141.0 (114.5, 210.0) 0.023
Insulin (µIU/mL)
Week 0 10.6 (5.0, 16.4) 0.588 10.5 (7.0, 13.7) 0.501 0.982
Week 8 10.5 (7.3, 14.2) 10.4 (7.9, 13.3) 0.910
HOMA-IR
Week 0 4.3 (1.2, 5.1) 0.355 3.7 (2.2, 5.3) 0.592 0.733
Week 8 3.5 (1.8, 4.5) 3.7 (2.5, 6.0) 0.414
TAC (g/dL protein)
Week 0 3.37±0.83b <0.001 4.26±0.54 0.154 <0.001
Week 8 4.22±0.48 4.44±0.43 0.132
MDA (nmol/mL)
Week 0 3.22±1.41 <0.001 2.31±1.19 0.23 0.027
Week 8 2.09±1.06 2.81±1.21 0.044
aMedian (25th, 75th percentiles) all such values; bMean±SD all such values; cP values refer to comparisons between week 0 and week 8 within groups (paired t-test or Wilcoxon as 
appropriate); dP values refer to comparisons between groups (independent t-test or Mann-Whitney U-test as appropriate). FBS = Fast blood sugar; TAC = Total antioxidant capacity; 
MDA = Malondialdehyde; SD = Standard deviation; HOMA-IR = Homeostatic model assessment for insulin resistance
Groups FBS (mg/dL) Insulin (µIU/mL) HOMA-IR MDA (nmol/mL) TAC (g/dL protein)
Tocotrienol enriched canola oil −15.4±20.1* 0 (−9.1, 46.0) −19.1 (−29.5, 60.6) −35.6* (−56.8, −17.3) 21.4* (11.5, 43.0)
Pure canola oil 3.9±24.9 −3.1 (−11.9, 15.1) −4.0 (−27.2, 36.4) 16.3 (−22.2, 124.3) 2.3 (−6.5, 17.1)
Figure 2: Differences in percent changes from baseline to 8 weeks in tocotrienol enriched canola oil (n = 23) and pure canola oil groups (n = 22). aP = 0.006, 
bP = 0.003, cP = 0.001 by independent t-test or Mann-Whitney U-test between two groups. Values are median (25th, 75th percentiles) except for FBS which is 
mean ± standard deviation. *Significantly different between groups (P < 0.05). HOMA-IR = Homeostatic model assessment for insulin resistance; TAC = Total 
antioxidant capacity; MDA = Malondialdehyde; SD = Standard deviation; FBS = Fast blood sugar
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In our study, 525 mg/day tocotrienols rich Vitamin E, 
equivalent to 200 mg/day tocotrienols, for 8 weeks reduced 
FBS by 15.4% in individuals with T2DM; this reduction was 
also significant compared with the pure canola oil group 
at end of the study (P = 0.006). TRF supplementation in 
streptozotocin-induced diabetic (STZ-diabetic) rats caused 
an improvement in glycemic status by decreasing FBS 
concentrations and glycated hemoglobin (HbA1C).[28,29] In an 
earlier intervention study in human, 6 mg/kg TRF treatment, 
in two divided doses, for 60 days did not affect either 
fasting plasma glucose or HbA1C in patients with T2DM.[20] 
Differences in glucose concentrations at baseline in those 
participants compared with ours may cause the inconsistent 
findings. The glucose concentrations in those participants 
were close to normal (mean ± SD: 113.5 ± 11.8 mg/dL) and 
they were glycemically stable, but our participants had a 
higher mean glucose concentration of 153.8 ± 55.5 mg/dL. 
Therefore, it seems that the blood glucose concentration 
might be a determinant of response to the tocotrienols 
supplementation and the hypoglycemic effect of tocotrienols 
are more likely to be observed in individuals with high FBS 
concentrations or poor glycemic control. The mechanisms 
of hypoglycemic activity of tocotrienols have not yet fully 
understood. It has been suggested that tocotrienols (and 
not tocopherols) can improve insulin sensitivity through 
activating peroxisome proliferator-activated receptors 
(PPARs). Binding of tocotrieols to PPAR promotes insulin 
mediated glucose uptake through increasing the expression 
of glucose transporter 4.[30] In addition, previous studies 
indicate improved liver structure and function following 
Vitamin E[31] or TRF treatment.[32] Therefore, the reduction 
in FBS observed in our study can also be attributed to 
improved hepatocellular function and reduced release of 
glucose from the liver.
Concentrations of antioxidants are lower in diabetes because 
of excessive production of reactive oxidative specious and 
increased oxidative stress. A weakened antioxidant defense 
system, in turn, can intensify oxidative stress.[3] The present 
study demonstrated that TRF improved oxidative status 
in diabetes patients; since it significantly increased TAC 
and decreased lipid peroxidation. Although at baseline 
the tocotrienols enriched canola oil group appeared to be 
exposed to higher oxidative stress, as documented by lower 
TAC and higher MDA, redox status was improved at the end 
of the study to a larger extent than in the pure canola oil.
In animal studies, tocotrienols administration could 
increase TAC in hypertensive rats.[33] Furthermore, TRF 
enhanced the concentrations of Vitamin C and superoxide 
dismutase activity and prevented an increase in MDA and 
DNA damage in STZ-induced diabetic rats.[29] In a dose-
response study in healthy individuals, the administration 
of 320 mg TRF was associated with a small significant 
increase (9.2%) in plasma TAC compared to baseline, 
in which was not significant compared with untreated 
group.[34] TRF supplementation in middle-aged and older 
adults at dose of 160 mg/day for 6 months attenuated serum 
advanced glycosylation end products and protein carbonyl 
content, the markers of protein oxidative damage, only 
in the individuals >50 years. MDA concentrations were 
also reduced in the >50 years old group after 3 months 
and remained low thereafter, but the change did not 
achieve statistical significance.[19] This age-dependent 
response to TRF supplementation might reflect that TRF 
supplementation in a population with the well-maintained 
antioxidant defense could not confer further improvement.
Tocotrienols may reduce the oxidative damage directly by 
exerting their antioxidant activity and as a consequence of 
improved counteracting the oxidative damage. In addition, 
the production of free radicals due to hyperglycemia might 
also be reduced by tocotrienols administration through a 
better control of glycemia. Reduced oxidative stress can 
improve insulin sensitivity, which in turn might decrease 
plasma triglyceride and free fatty acid through down-
regulation of lipolysis. This down-regulation of lipolysis 
induced by the effect of insulin on adipose tissue might also 
lead to a decline in lipid peroxidation.[32,35]
Tocotrienols are thought to have greater antioxidant 
properties than α-tocopherol.[11,12] Indeed, tocotrienols have 
a unique conformation because of their three double bonds 
hydrocarbon tail which allows for better distributions in the 
fatty layers of the cell membrane.[36,37] Only pharmacological 
doses of α-tocopherol were associated with improving 
insulin action, inflammatory or oxidative markers.[31,35,38] 
The tocotrienols rich Vitamin E mixture in the present study 
contains 38.4% tocotrienols and 12.6% tocopherol. Therefore, 
the improved redox status in our study does not seem to 
be attributed to tocopherols. However, tocopherols might 
affect the responses to tocotrienols; as an example, it has 
been demonstrated that TRF preparations containing 20% 
or more α-tocopherol attenuate the hypocholesterolemic 
effect of γ-tocotrienols.[39]
In this study, we added tocotrienols to canola oil in order to 
improve its absorption and patient compliance. Because of 
the low content of tocotrienols in edible natural sources, it 
does not seem that the dietary sources can provide sufficient 
amounts of tocotrienols.[40] Thus, promoting intakes 
of tocotrienols through supplements appears prudent 
especially in patients with diabetes. Fortification of oil with 
this vitamin is an appropriate way to increase its intake.
Some limitations of our study should be mentioned. First, 
we did not measure blood levels of active components of the 
supplementation to confirm the compliance with treatment. 
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Previous studies indicate that blood concentrations of 
tocotrienols cannot be detectable in the fasted state, even 
after supplementation with tocotrienols.[34,41] Since the 
blood samples were collected after 10-12 h of fasting in the 
present study, plasma tocotrienols concentrations were not 
an appropriate marker to confirm treatment compliance 
in our study. However, plasma tocopherol concentrations 
could be used instead of tocotrienols. Second, since we 
did not measured lipid profile in our study, we could not 
show the possible effect of tocotrienol on lipid metabolism 
in our study. Finally, not measuring any inflammatory 
markers and hepatic enzyme concentrations are the other 
limitations of our study. Therefore, we could not determine 
the possible mechanism of the effectiveness of tocotrienols 
in our study.
CONCLUSION
Administration of 525 mg tocotrienols rich Vitamin E or 200 
mg total tocotrienols added to canola oil for 8 weeks were 
well-tolerated and improved blood glucose, antioxidant 
capacity, and oxidative stress in T2DM patients with poor 
control of glucose. The optimal doses and duration of TRF 
administration to show the most favorable effects on T2DM 
patients remain to be determined. Furthermore, studies 
with individual tocotrienols are needed since the pure 
components may lead to different responses as compared 
to the mixture. Investigations of the effects of tocotrienols 
on hepatocell function, hepatic enzyme concentrations, and 
inflammatory markers are also required to elucidate the 
mechanisms of tocotrienols actions.
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